Veterinary Medicines

Danilon Equidos NF 1.5 g/sachet granules in sachet for horses and ponies

Authorised
  • Suxibuzone
Download as PDF

Product identification

Medicine name:
Danilon Equidos NF 1.5 g/sachet granules in sachet for horses and ponies
Suxibuzone Ecuphar 1,5 g granulas paciņā zirgiem un ponijiem
Active substance:
  • Suxibuzone
Target species:
  • Horse (non food-producing)
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Suxibuzone
    1.59
    gram(s)
    /
    3.00
    gram(s)
Pharmaceutical form:
  • Granules in sachet
Withdrawal period by route of administration:
  • Oral use
    • Horse (non food-producing)
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AA90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Latvia
Package description:
  • (ID2): 1 Box with 60 Sachet (Orientated PolyAmide, Aluminium, PolyEthylene) with 3 gram(s) (180 gram(s))
  • (ID1): 1 Box with 18 Sachet (Orientated PolyAmide, Aluminium, PolyEthylene) with 3 gram(s) (54 gram(s))

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ecuphar
Marketing authorisation date:
Manufacturing sites for batch release:
  • Recipharm Parets S.L.
Responsible authority:
  • Food And Veterinary Service
Authorisation number:
  • V/DCP/20/0057
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0326/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Romania
  • Slovakia
  • Slovenia

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 28/03/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."